Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Uncovering the role of hnRNP K, an RNA-binding protein, in B-cell lymphomas.

Gallardo M, Malaney P, Aitken MJL, Zhang X, Link TM, Shah V, Alybayev S, Wu MH, Pageon LR, Ma H, Jacamo R, Yu L, Xu-Monette ZY, Steinman H, Lee HJ, Sarbassov D, Rapado I, Barton MC, Martinez-Lopez J, Bueso-Ramos C, Young KH, Post SM.

J Natl Cancer Inst. 2019 May 11. pii: djz078. doi: 10.1093/jnci/djz078. [Epub ahead of print]

PMID:
31077320
2.

Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasms.

Cortés AA, Diaz RA, Hernández-Campo P, Gorrochategui J, Primo D, Robles A, Morales ML, Ballesteros J, Rapado I, Gallardo M, Linares M, Martínez-López J.

Haematologica. 2019 May;104(5):937-946. doi: 10.3324/haematol.2018.201038. Epub 2018 Dec 13.

3.

Correction: Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes.

Cedena MT, Rapado I, Santos-Lozano A, Ayala R, Onecha E, Abaigar M, Such E, Ramos F, Cervera J, Díez-Campelo M, Sanz G, Rivas JH, Lucía A, Martínez-López J.

Oncotarget. 2018 Jul 20;9(56):30936. doi: 10.18632/oncotarget.25856. eCollection 2018 Jul 20.

4.

A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia.

Onecha E, Linares M, Rapado I, Ruiz-Heredia Y, Martinez-Sanchez P, Cedena T, Pratcorona M, Oteyza JP, Herrera P, Barragan E, Montesinos P, Vela JAG, Magro E, Anguita E, Figuera A, Riaza R, Martinez-Barranco P, Sanchez-Vega B, Nomdedeu J, Gallardo M, Martinez-Lopez J, Ayala R.

Haematologica. 2019 Feb;104(2):288-296. doi: 10.3324/haematol.2018.194712. Epub 2018 Aug 9.

5.

Concurrent progressive multifocal leukoencephalopathy and central nervous system infiltration by multiple myeloma: A case report.

Ruiz-Heredia Y, Sanchez-Vega B, Barrio S, Linares M, Rapado I, Braggio E, Stewart K, Folgueira MD, Ramos A, Collado L, Ruiz J, Toldos O, Hernandez-Lain A, Martinez-Lopez J.

J Oncol Pharm Pract. 2019 Jun;25(4):998-1002. doi: 10.1177/1078155218769367. Epub 2018 Apr 24.

PMID:
29690814
6.

Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes.

Cedena MT, Rapado I, Santos-Lozano A, Ayala R, Onecha E, Abaigar M, Such E, Ramos F, Cervera J, Díez-Campelo M, Sanz G, Rivas JH, Lucía A, Martínez-López J.

Oncotarget. 2017 Oct 27;8(63):106948-106961. doi: 10.18632/oncotarget.22157. eCollection 2017 Dec 5. Erratum in: Oncotarget. 2018 Jul 20;9(56):30936.

7.

Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia.

Forero-Castro M, Robledo C, Benito R, Bodega-Mayor I, Rapado I, Hernández-Sánchez M, Abáigar M, Maria Hernández-Sánchez J, Quijada-Álamo M, María Sánchez-Pina J, Sala-Valdés M, Araujo-Silva F, Kohlmann A, Luis Fuster J, Arefi M, de Las Heras N, Riesco S, Rodríguez JN, Hermosín L, Ribera J, Camos Guijosa M, Ramírez M, de Heredia Rubio CD, Barragán E, Martínez J, Ribera JM, Fernández-Ruiz E, Hernández-Rivas JM.

Br J Cancer. 2017 Jul 11;117(2):256-265. doi: 10.1038/bjc.2017.152. Epub 2017 May 30.

8.

Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma.

Martinez-Lopez J, Sanchez-Vega B, Barrio S, Cuenca I, Ruiz-Heredia Y, Alonso R, Rapado I, Marin C, Cedena MT, Paiva B, Puig N, Mateos MV, Ayala R, Hernández MT, Jimenez C, Rosiñol L, Martínez R, Teruel AI, Gutiérrez N, Martin-Ramos ML, Oriol A, Bargay J, Bladé J, San-Miguel J, Garcia-Sanz R, Lahuerta JJ.

Leukemia. 2017 Jun;31(6):1446-1449. doi: 10.1038/leu.2017.58. Epub 2017 Feb 17. No abstract available.

9.

Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array.

García-Sanz R, Corchete LA, Alcoceba M, Chillon MC, Jiménez C, Prieto I, García-Álvarez M, Puig N, Rapado I, Barrio S, Oriol A, Blanchard MJ, de la Rubia J, Martínez R, Lahuerta JJ, González Díaz M, Mateos MV, San Miguel JF, Martínez-López J, Sarasquete ME; GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group.

Hematol Oncol. 2017 Dec;35(4):746-751. doi: 10.1002/hon.2337. Epub 2016 Sep 8.

PMID:
27605156
10.

Differentiation stage of myeloma plasma cells: biological and clinical significance.

Paiva B, Puig N, Cedena MT, de Jong BG, Ruiz Y, Rapado I, Martinez-Lopez J, Cordon L, Alignani D, Delgado JA, van Zelm MC, Van Dongen JJ, Pascual M, Agirre X, Prosper F, Martín-Subero JI, Vidriales MB, Gutierrez NC, Hernandez MT, Oriol A, Echeveste MA, Gonzalez Y, Johnson SK, Epstein J, Barlogie B, Morgan GJ, Orfao A, Blade J, Mateos MV, Lahuerta JJ, San-Miguel JF.

Leukemia. 2017 Feb;31(2):382-392. doi: 10.1038/leu.2016.211. Epub 2016 Aug 1.

11.

Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis.

Paiva B, Martinez-Lopez J, Corchete LA, Sanchez-Vega B, Rapado I, Puig N, Barrio S, Sanchez ML, Alignani D, Lasa M, García de Coca A, Pardal E, Oriol A, Garcia ME, Escalante F, González-López TJ, Palomera L, Alonso J, Prosper F, Orfao A, Vidriales MB, Mateos MV, Lahuerta JJ, Gutierrez NC, San Miguel JF.

Blood. 2016 Jun 16;127(24):3035-9. doi: 10.1182/blood-2015-10-673095. Epub 2016 Apr 11.

PMID:
27069257
12.

hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic Malignancies.

Gallardo M, Lee HJ, Zhang X, Bueso-Ramos C, Pageon LR, McArthur M, Multani A, Nazha A, Manshouri T, Parker-Thornburg J, Rapado I, Quintas-Cardama A, Kornblau SM, Martinez-Lopez J, Post SM.

Cancer Cell. 2015 Oct 12;28(4):486-499. doi: 10.1016/j.ccell.2015.09.001. Epub 2015 Sep 24.

13.

Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality.

Martínez-López J, Paiva B, López-Anglada L, Mateos MV, Cedena T, Vidríales MB, Sáez-Gómez MA, Contreras T, Oriol A, Rapado I, Teruel AI, Cordón L, Blanchard MJ, Bengoechea E, Palomera L, de Arriba F, Cueto-Felgueroso C, Orfao A, Bladé J, San Miguel JF, Lahuerta JJ; Spanish Multiple Myeloma Group / Program for the Study of Malignant Blood Diseases Therapeutics (GEM / PETHEMA) Cooperative Study Group.

Blood. 2015 Aug 13;126(7):858-62. doi: 10.1182/blood-2015-04-638742. Epub 2015 Jun 18.

14.

CALR mutations screening should not be studied in splanchnic vein thrombosis.

Castro N, Rapado I, Ayala R, Martinez-Lopez J.

Br J Haematol. 2015 Aug;170(4):588-9. doi: 10.1111/bjh.13314. Epub 2015 Feb 2. No abstract available.

PMID:
25648180
15.

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma.

Martinez-Lopez J, Lahuerta JJ, Pepin F, González M, Barrio S, Ayala R, Puig N, Montalban MA, Paiva B, Weng L, Jiménez C, Sopena M, Moorhead M, Cedena T, Rapado I, Mateos MV, Rosiñol L, Oriol A, Blanchard MJ, Martínez R, Bladé J, San Miguel J, Faham M, García-Sanz R.

Blood. 2014 May 15;123(20):3073-9. doi: 10.1182/blood-2014-01-550020. Epub 2014 Mar 19.

16.

JAK2 exon 12 mutations were not found in liver transplant recipients with or without pretransplant portal vein thrombosis.

Ayala R, Rapado I, Grande S, Moreno E, Martínez-López J.

Eur J Gastroenterol Hepatol. 2014 Mar;26(3):362-3. doi: 10.1097/MEG.0000000000000022. No abstract available.

PMID:
24463542
17.

RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia.

Papaemmanuil E, Rapado I, Li Y, Potter NE, Wedge DC, Tubio J, Alexandrov LB, Van Loo P, Cooke SL, Marshall J, Martincorena I, Hinton J, Gundem G, van Delft FW, Nik-Zainal S, Jones DR, Ramakrishna M, Titley I, Stebbings L, Leroy C, Menzies A, Gamble J, Robinson B, Mudie L, Raine K, O'Meara S, Teague JW, Butler AP, Cazzaniga G, Biondi A, Zuna J, Kempski H, Muschen M, Ford AM, Stratton MR, Greaves M, Campbell PJ.

Nat Genet. 2014 Feb;46(2):116-25. doi: 10.1038/ng.2874. Epub 2014 Jan 12.

18.

Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm.

Barrio S, Gallardo M, Arenas A, Ayala R, Rapado I, Rueda D, Jimenez A, Albizua E, Burgaleta C, Gilsanz F, Martinez-Lopez J.

Br J Haematol. 2013 Jun;161(5):667-76. doi: 10.1111/bjh.12308. Epub 2013 Apr 5.

PMID:
23560534
19.

Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.

Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, Pellagatti A, Wainscoat JS, Hellstrom-Lindberg E, Gambacorti-Passerini C, Godfrey AL, Rapado I, Cvejic A, Rance R, McGee C, Ellis P, Mudie LJ, Stephens PJ, McLaren S, Massie CE, Tarpey PS, Varela I, Nik-Zainal S, Davies HR, Shlien A, Jones D, Raine K, Hinton J, Butler AP, Teague JW, Baxter EJ, Score J, Galli A, Della Porta MG, Travaglino E, Groves M, Tauro S, Munshi NC, Anderson KC, El-Naggar A, Fischer A, Mustonen V, Warren AJ, Cross NC, Green AR, Futreal PA, Stratton MR, Campbell PJ; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium.

N Engl J Med. 2011 Oct 13;365(15):1384-95. doi: 10.1056/NEJMoa1103283. Epub 2011 Sep 26.

20.

Epigenomic profiling in polycythaemia vera and essential thrombocythaemia shows low levels of aberrant DNA methylation.

Barrio S, Gallardo M, Albizua E, Jimenez A, Rapado I, Ayala R, Gilsanz F, Martin-Subero JI, Martinez-Lopez J.

J Clin Pathol. 2011 Nov;64(11):1010-3. doi: 10.1136/jclinpath-2011-200175. Epub 2011 Aug 6.

PMID:
21821860
21.

Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia.

Albizua E, Gallardo M, Barrio S, Rapado I, Jimenez A, Ayala R, Rueda D, Sanchez-Espiridion B, Puigdecanet E, Espinet B, Florensa L, Besses C, Martinez-Lopez J.

Ann Hematol. 2011 Aug;90(8):939-46. doi: 10.1007/s00277-011-1179-2. Epub 2011 Feb 18.

PMID:
21331593
22.

Relationship between deoxycytidine kinase (DCK) genotypic variants and fludarabine toxicity in patients with follicular lymphoma.

Rivero A, Rapado I, Tomás JF, Montalbán C, de Oña R, Paz-Carreira J, Canales M, Martínez R, Sánchez-Godoy P, de Sevilla AF, de la Serna J, Martínez-López J.

Leuk Res. 2011 Apr;35(4):431-7. doi: 10.1016/j.leukres.2010.09.026. Epub 2010 Oct 27.

PMID:
21030078
23.

Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide.

Martínez-López J, Rivero A, Rapado I, Montalbán C, Paz-Carreira J, Canales M, Martínez R, Sánchez-Godoy P, Fernández de Sevilla A, Peñalver FJ, Gonzalez M, Prieto E, Salar A, Burgaleta C, Queizán JA, Peñarrubia MJ, Monteagudo MD, Cabrera C, De la Serna J, Tomás JF.

Leuk Lymphoma. 2009 Aug;50(8):1283-9. doi: 10.1080/10428190903040006.

PMID:
19557622
24.

High resolution melting analysis for JAK2 Exon 14 and Exon 12 mutations: a diagnostic tool for myeloproliferative neoplasms.

Rapado I, Grande S, Albizua E, Ayala R, Hernández JA, Gallardo M, Gilsanz F, Martinez-Lopez J.

J Mol Diagn. 2009 Mar;11(2):155-61. doi: 10.2353/jmoldx.2009.080110.

25.

Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases.

Rapado I, Albizua E, Ayala R, Hernández JA, Garcia-Alonso L, Grande S, Gallardo M, Gilsanz F, Martinez-Lopez J.

Ann Hematol. 2008 Sep;87(9):741-9. doi: 10.1007/s00277-008-0512-x. Epub 2008 Jun 25.

PMID:
18575865

Supplemental Content

Loading ...
Support Center